Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patients

[1]  Y. Soong,et al.  Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer. , 2011, Taiwanese journal of obstetrics & gynecology.

[2]  P. Devroey,et al.  An OHSS-Free Clinic by segmentation of IVF treatment. , 2011, Human reproduction.

[3]  E. Ekerhovd.  [Use of GnRH antagonist for in vitro fertilization]. , 2011, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[4]  Kristin N. Smith,et al.  A prospective investigation into the reasons why insured United States patients drop out of in vitro fertilization treatment. , 2010, Fertility and sterility.

[5]  E. Kolibianakis,et al.  Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). , 2010, Human reproduction.

[6]  F. Zhioua,et al.  [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. , 2009, La Tunisie medicale.

[7]  P. Devroey,et al.  A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol , 2009, Human reproduction.

[8]  Marinus J C Eijkemans,et al.  A detailed cost analysis of in vitro fertilization and intracytoplasmic sperm injection treatment. , 2008, Fertility and sterility.

[9]  A. Coomarasamy,et al.  A three-arm randomised controlled trial comparing Gonadotrophin Releasing Hormone (GnRH) agonist long regimen versus GnRH agonist short regimen versus GnRH antagonist regimen in women with a history of poor ovarian response undergoing in vitro fertilisation (IVF) treatment: Poor responders intervent , 2007, Reproductive health.

[10]  J. Passchier,et al.  The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy. , 2007, Human reproduction.

[11]  G. Pennings,et al.  Coming soon to your clinic: patient-friendly ART. , 2007, Human reproduction.

[12]  A. Abou-Setta,et al.  Gonadotrophin-releasing hormone antagonists for assisted conception. , 2006, The Cochrane database of systematic reviews.

[13]  E. Kolibianakis,et al.  GnRH antagonists in ovarian stimulation for IVF. , 2006, Human reproduction update.

[14]  M. Rajkhowa,et al.  Reasons for discontinuation of IVF treatment: a questionnaire study. , 2006, Human reproduction.

[15]  P. Crosignani,et al.  Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. , 2005, Human reproduction.

[16]  D. Hornung,et al.  Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. , 2005, Human reproduction.

[17]  M. Ludwig,et al.  Optimierung der Erfolgsaussichten in einem IVF-Programm , 2004 .

[18]  N. Macklon,et al.  What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment. , 2004, Human reproduction.

[19]  C. Bergh,et al.  Why do couples discontinue in vitro fertilization treatment? A cohort study. , 2004, Fertility and sterility.

[20]  J. Itskovitz‐Eldor,et al.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  E. Kuczynski,et al.  Supracervical hysterectomy versus total abdominal hysterectomy: perceived effects on sexual function , 2002, BMC women's health.

[22]  G. Borm,et al.  Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. , 2000, Human reproduction.

[23]  P. Devroey,et al.  Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. , 2000, Human reproduction.

[24]  R. Frydman,et al.  Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). , 2000, Fertility and sterility.

[25]  J. Engel,et al.  GnRH agonists and antagonists in assisted reproduction: pregnancy rate. , 2006, Reproductive biomedicine online.

[26]  M. Ludwig,et al.  [Optimisation of possible success in an IVF program]. , 2004, Zentralblatt für Gynäkologie.

[27]  F. Olivennes.  Patient-friendly ovarian stimulation. , 2003, Reproductive biomedicine online.

[28]  F. Broekmans,et al.  A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  D. Goldhamer,et al.  Reproductive Biology and Endocrinology , 2003 .

[30]  Z. Rosenwaks,et al.  Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. , 2001, Fertility and sterility.

[31]  T. European Middle East Orgalutran Study Group*.  Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. , 2001, Human reproduction.